Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2007

The Pharma Closeout tracks 30 deals, $110.7B in disclosed deal value, 27 with a post-close Outcome Score for the year 2007.

Median Critic Score: 75  ·  Median Outcome Score: 48

Best outcome: Sanofi SA / Regeneron Pharmaceuticals, Inc. (97)  ·  Weakest outcome: Pfizer Inc. / Coley Pharmaceutical Group Inc. (13)

All 30 deals

• Sanofi SA / Regeneron Pharmaceuticals, Inc. — 2007 · $1.0B · Worked — the deal delivered on its rationale.
• Shire plc / New River Pharmaceuticals Inc. — 2007 · $2.6B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Ventana Medical Systems Inc. — 2007 · $3.4B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / MedImmune Inc. — 2007 · $15.6B · Worked — the deal delivered on its rationale.
• Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. — 2007 · $2.3B · Worked — the deal delivered on its rationale.
• Mylan Laboratories Inc. / Merck Generics (Merck KGaA) — 2007 · $6.7B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Genentech, Inc. (Roche Group) — 2007 · Worked — the deal delivered on its rationale.
• Bayer AG / Schering AG (residual squeeze-out) — 2007 · $985M · Largely worked — most objectives met.
• Watson Pharmaceuticals Inc. / Andrx Corporation — 2007 · $1.9B · Largely worked — most objectives met.
• Nycomed / Altana Pharma AG — 2007 · $4.5B · Mixed — partial payoff, real shortfalls.
• Schering-Plough Corp. / Organon International — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / BioVeris Corporation — 2007 · $600M · Mixed — partial payoff, real shortfalls.
• Nycomed / Bradley Pharmaceuticals — 2007 · $346M · Mixed — partial payoff, real shortfalls.
• Schering-Plough Corp. / Organon & Co. — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Schering-Plough Corp. / Organon BioSciences N.V. (Akzo Nobel) — 2007 · $14.5B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Organon & Co. — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. — 2007 · $1.6B · Mixed — partial payoff, real shortfalls.
• Mitsubishi Pharma Corp. / Tanabe Seiyaku Co. Ltd. — 2007 · $4.3B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2007 · $1.0B · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Domantis Limited — 2007 · $454M · Underwhelmed — fell short of the thesis.
• Eisai Co. Ltd. / MGI Pharma Inc. — 2007 · $3.9B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Therapeutic Human Polyclonals Inc. — 2007 · $56M · Did not work — the deal failed to deliver.
• Amgen Inc. / Ilypsa Inc. — 2007 · $420M · Did not work — the deal failed to deliver.
• Roche Holding AG / 454 Life Sciences Corp. — 2007 · $155M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Coley Pharmaceutical Group Inc. — 2007 · $164M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Arrow Therapeutics Ltd. — 2007 · $150M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / NovaCardia Inc. — 2007 · $366M · Did not work — the deal failed to deliver.
• Abbott Laboratories / Genentech Inc. (Roche Group) — 2007
• Merck KGaA / ImClone Systems Inc. — 2007
• Bristol-Myers Squibb Company / Adnexus Therapeutics Inc. — 2007 · $430M

← Deal Library  ·  Interactive search  ·  How we score deals